Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response

Fig. 2

source studies are listed in Additional file 1: Table S2. Also see Additional file 1: Figure S2, S3

Curated gene expression analyses of publicly available microarray datasets in PD using Gene Expression Omnibus (GEO). A NFE2L2 (nuclear factor, Erythroid 2 Like 2, NRF2), B KEAP1 (Kelch Like ECH Associated Protein 1, NRF2 inhibitor protein), C, D NRF2 anti-oxidant response mediators, HMOX1 (Heme Oxygenase 1, in C), GCLC (Glutamate-Cysteine Ligase Catalytic Subunit, in D), and (E, F) Pro-apoptotic caspases, CASP3 (Caspase 3, in E) and CASP6 (Caspase 6, in F). The values across the datasets are expressed relative to the controls in each microarray dataset, i.e., mean value of control samples = 1 (a.u., arbitrary units). Error bars represent standard deviation of the mean, s.d. In GSE7621-SN (substantia nigra); controls (Ctrl, n = 9) and PD (Parkinson Disease cases, n = 16); in GSE43490-SN (substantia nigra; controls, n = 6 and PD, n = 8), DMX (dorsal motor nucleus of vagus; controls, n = 5 and PD, n = 8), LC (locus coeruleus; controls, n = 7 and PD, n = 8); in GSE20146—GPi (globus pallidus interna; controls, n = 10 and PD, n = 10). Pair-wise comparisons were assessed by Mann–Whitney test—only significant differences (* = p ≤ 0.05, ** = p ≤ 0.01) are highlighted. Probe IDs, microarray platforms and

Back to article page